Although previous studies modified two components of conditionally replicating adenoviruses (CRAs), which selectively replicate in and kill cancer cells, the most accurate ways to achieve increased cancer specificity (that is, safety) without reducing the anticancer (that is, therapeutic) effects are unknown. Here, we generated two types of survivin-responsive m-CRAs (Surv.mCRAs), Surv.m-CRA-CMVp and Surv.m-CRA-OCp, which use two and three different mechanisms to target cancer, that is, early region 1A (E1A) regulated by the survivin promoter and mutated E1BD55K regulated by the ubiquitously active cytomegalovirus promoter and cancer/tissue-specific osteocalcin promoter, respectively, and carefully examined their safety and anticancer effects. Endogenous osteocalcin mRNA was expressed and further enhanced by vitamin D 3 in all osteosarcoma and prostate cancer cell lines and human osteoblasts, but not in human fibroblasts. The osteocalcin promoter activity was weak even with vitamin D 3 treatment in these osteocalcin-expressing cancers, leading to low E1BD55K expression after Surv.m-CRA-OCp infection. Nevertheless, Surv.m-CRA-OCp had significantly increased cancer specificity without reduced anticancer effects in both in vitro and in vivo experiments. The unexpected but favorable fact that strong activity of an altered E1B promoter is unnecessary indicates that the majority of cancer/tissue-specific promoters may be used to generate ideal m-CRAs and will advance the development of m-CRA-based cancer therapies.
Introduction
Conditionally replicating adenoviruses (CRAs) selectively replicate in and kill cancer cells and are therefore attractive anticancer agents. 1, 2 CRAs are predominantly classified into two categories. 3 The first CRA category has attenuated viral replication only in normal cells because of specific mutations in the adenoviral early gene 1 (E1), such as E1AD24 and E1BD55K that lack the Rb-and p53-binding sites in the early region 1A (E1A) and 1B (E1B), respectively. [4] [5] [6] In the second category, E1 expression is altered in a cancer-specific manner because the promoter driving E1, particularly E1A, is replaced. 7 Although previous studies demonstrated that both strategies are efficacious, it is possible that a single cancer-specific factor will be insufficient to strictly target cancer, potentially leading to adverse side effects in future clinical trials. 8 A combination of multiple cancerspecific factors may be a promising approach to increase the safety of CRAs; 1, 9, 10 however, it is largely unclear whether and to what degree the anticancer effects are decreased by introducing multiple cancer-specific factors. These insufficient analyses have partially occurred because constructing diversely modified CRAs is time consuming and labor intensive.
To solve this problem, we previously developed a method to efficiently construct diverse CRAs that can specifically target cancers using multiple factors (m-CRAs). 8 Using this method, we previously generated two types of survivin-responsive m-CRAs (Surv.mCRAs), in which E1B was mutated to E1BD55K and either the wild-type E1A or mutant E1AD24 gene was regulated by the promoter of survivin, a new member of the inhibitor of apoptosis gene family. 7, 11, 12 These modified CRAs were promising because the survivin promoter and the resulting Surv.m-CRAs exhibited both a stronger and more cancer-selective phenotype (that is, transgene expression and anticancer effects, respectively) than the telomerase reverse transcriptase promoter and telomerase reverse transcriptase-responsive m-CRA (Tert.m-CRA), which is currently one of the best CRAs. 7, 13 A careful comparative study of both Surv.mCRAs revealed that additional modifications of E1A to E1AD24 downstream of the survivin promoter provided neither increased cancer specificity nor reduced the anticancer effects, suggesting that this combination is not essential to improve m-CRAs, at least Surv.m-CRAs. 7 On the other hand, a few previous studies obtained increased cancer specificity by replacing the E1B promoters with cancer-specific promoters in addition to regulating E1A with a different cancer-specific promoter. 9, 10 However, the actual utility of this combination remains unclear because the original and modified CRAs were not sufficiently compared. In particular, several crucial and unanswered questions remain, including how much E1B or E1BD55K (E1B/E1BD55K) expression is necessary and how strong of a different cancer-/tissuespecific promoter is necessary to drive E1B/E1BD55K expression to increase cancer specificity without reducing the anticancer effects. Because many cancer/tissuespecific promoters have weak activity, [13] [14] [15] it is unclear whether this strategy will consistently yield clinically useful m-CRAs.
To clarify this issue, we carefully analyzed the characteristics of two types of Surv.m-CRAs, the original Surv.m-CRA-CMVp and a newly constructed Surv.m-CRA-OCp that express E1BD55K under the ubiquitously strong, human cytomegalovirus immediate-early gene enhancer/promoter (CMV promoter) and cancer/tissuespecific osteocalcin promoter, respectively. We chose the osteocalcin promoter because osteocalcin, a major noncollagenous Gla protein that is natively produced by osteoblasts, has a vitamin D 3 (VD 3 )-responsive element that is activated by VD 3 . [16] [17] [18] These analyses showed that the strong activity of an altered cancer/tissue-specific E1B promoter is not essential. This finding is unexpected but meaningful because many popular cancer/tissue-specific promoters can now be used to generate ideal m-CRAs, which will open up an innovative therapeutic strategy.
Materials and methods

Cells and cell culture
Four human osteosarcoma cell lines (HOS-MNNG, MG-63, KHOS-NP and SaOS-2), two human prostate cancer cell lines (DU145 and PC-3), human primary lung fibroblasts (WI-38) and human osteoblasts (NHOst) were obtained and cultured as described previously. 7, 13, 19, 20 Reverse transcription-polymerase chain reaction analysis At 2 days after culturing cells with media in the presence or absence of 50 nM VD 3 (Sigma-Aldrich, Tokyo, Japan), total RNA was extracted from cells and reverse transcription-polymerase chain reaction analyses were performed using the primer sets and annealing temperatures that were described previously. 7, 14, 21 The osteocalcin/hypoxantine-phosphoribosyl-transferase (a representative housekeeping gene) mRNA ratio was calculated to compare the relative effects of VD 3 in individual cells and standardize the unavoidable variability in the polymerase chain reaction data as described. 21 
Generation of adenoviruses
The human osteocalcin promoter (À886 to þ 3) was cloned by polymerase chain reaction using genomic DNA from SaOS-2 cells and the following primers: sense-hOC.pr, 5 0 -CTGCAGGGTCAGGAGGAGAA-3 0 and antisensehOC.pr, 5
0 -CATGGTGTCTCGGTGGCTGC-3 0 . Surv.m-CRA-CMVp and Surv.m-CRA-OCp, which contained wild-type E1A downstream of the survivin promoter, E1BD55K downstream of the CMV promoter or the human osteocalcin promoter, and the enhanced green fluorescent protein (EGFP) gene downstream of the CMV promoter, were generated using the novel m-CRA construction method that we developed previously. 7, 8 An E1-deleted replication-defective adenovirus that expressed no gene (Ad.dE1.3), the LacZ gene under the transcriptional control of the Rous sarcoma virus longterminal repeat (RSV promoter; Ad.RSV-LacZ) or the osteocalcin promoter (Ad.OC-LacZ), or EGFP under the cytomegalovirus enhancer and b-actin promoter (Ad.CA-EGFP) were generated and prepared as described previously. 15, 19, 20, [22] [23] [24] Adenoviral gene transduction efficiencies and promoter activities The adenoviral gene transduction efficiency (AGTE) for each cell in vitro was assessed by infecting the cells with Ad.CA-EGFP at several multiplicity of infections (MOIs), detaching the cells after 48 h, and then counting the EGFP-positive cells among the total cells under a fluorescent microscope. The promoter activities were examined as previously described with some modifications. 7, 13, 15 Briefly, the cells (5 Â 10 5 cells per plate) were infected with Ad.OC-LacZ or Ad.RSV-LacZ at an MOI of 30 for 1 h and then incubated with fresh media in the presence or absence of 50 nM VD 3 . The cells were collected at 48 h post-infection, and the b-gal activity was measured using a b-Galactosidase Enzyme Assay System (Promega, Madison, WI) as described previously. 13, 15 Western blot analysis Cells were either mock infected or infected with Surv.m-CRA-CMVp, Surv.m-CRA-OCp or Ad.dE1.3 at an MOI of 5 for 1 h and then incubated with fresh media in the presence or absence of 50 nM VD 3 for 3 days. The cells were lysed in buffer containing 50 mM Tris-HCl (pH7.5), 150 mM NaCl, 0.5% NP-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 0.5 mM phenylmethylsulfonyl fluoride (Nacalai Tesque, Kyoto, Japan) and a Protease inhibitor cocktail (Sigma-Aldrich). After electrophoresing 50 mg of protein, western blot analysis was performed using an anti-adenovirus 2 E1B 19-kDa primary antibody (Calbiochem, Darmstadt, Germany), horseradish peroxidase-conjugated anti-mouse immunoglobulin G secondary antibody (Invitrogen, Carlsbad, CA) and Chemi-Lumi One (Nacalai Tesque) according to the manufacturers' protocols and as described previously.
14,19 b-Actin was used as an internal control and detected in the same manner.
Cytotoxic effects in vitro
Cells in 96-well plates were infected with each adenovirus at various MOIs, and cell viability was determined after 3 and 5 days using the WST-8 assay (Dojindo Laboratories, Mashiki, Japan) as described previously. 7, 15 Therapeutic effects in in vivo animal experiments Subcutaneous tumor mouse models were generated using HOS-MNNG cells and examined for therapeutic effects as previously described with the minor modification that the number of viral injections was increased from one to two. 7 Briefly, HOS-MNNG cells (5 Â 10 6 cells) were injected subcutaneously into athymic nude mice. A measure of 50 ml of vehicle containing 1 Â 10 8 plaque-
or 50 ml of phosphate-buffered saline alone (n ¼ 9) was injected two times on days 0 and 3 into the subcutaneous tumor with a size ranging from 6 to 10 mm in diameter. Tumor size was monitored twice weekly and the tumor volume was calculated as described previously. 7 For histopathological analyses, the tumors were collected 35 days after the initial viral injections, fixed and stained with hematoxylin and eosin.
The animal protocols were approved by the Animal Research Committee of Kagoshima University. All animal experiments were conducted in accordance with the NIH Guidelines for the Care and Use of Laboratory Animals.
Statistical analysis
Data are represented as the means ± standard errors (s.e.). Statistical significance was determined using the Tukey's test. Po0.05 was considered statistically significant.
Results
Expression of endogenous survivin and osteocalcin mRNAs in osteosarcoma and prostate cancer cell lines
In accordance with our study and others, 7,25 survivin mRNA was expressed at moderate to high levels in all of the examined osteosarcoma and the prostate cancer cell lines, but the expression level was very low or undetectable in normal fibroblasts and osteoblasts ( Figure 1 ). On the other hand, osteocalcin mRNA was expressed at various levels and further enhanced by VD 3 not only in osteosarcoma and prostate cancer cell lines, but also in normal osteoblasts ( Figure 1 ). Osteocalcin mRNA expression was very low or undetectable and was not prominently enhanced by VD 3 in normal fibroblasts.
Various AGTEs in cells
Ad.CA-EGFP infection at serially diluted MOIs yielded various AGTEs among individual cell types. The AGTEs were high in two osteosarcoma cell lines (HOS-MNNG and KHOS-NP) and normal fibroblasts (WI-38), moderate in two prostate cancer cell lines (PC-3 and DU145), and low in two osteosarcoma cell lines (MG-63, SaOS-2) and normal osteoblasts (NHOst) (Figure 2 ). VD 3 -dependent enhancement of the osteocalcin promoter activity The activities of the osteocalcin and control RSV promoters and their VD 3 -dependent enhancement in individual cells were examined after infecting with Ad.OC-LacZ or Ad.RSV-LacZ and then measuring the b-gal activity. Whereas the level of b-gal activity after infecting with the control Ad.RSV-LacZ, which includes the actual RSV promoter activity and yielded different AGTEs, varied among cell types, it was not prominently enhanced by VD 3 in any of the cell types (Figure 3a) . On the other hand, the osteocalcin promoter activity was much lower than the RSV promoter activity in all of the osteosarcoma cells and fibroblasts without the addition of VD 3 . Notably, the osteocalcin promoter activity was drastically enhanced by VD 3 in osteocalcin-expressing cells (HOS-MMMG, MG-63 and KHOS-NP), except for SaOS-2 cells that had a low AGTE. In contrast, the osteocalcin promoter activity was not enhanced by VD 3 in WI-38 fibroblasts that demonstrated a high AGTE. Interestingly, the osteocalcin promoter activities in both of the prostate cancer cell lines (DU145 and PC-3) were much higher than those in all of the osteosarcoma cell lines and were enhanced three-to fourfold by VD 3 (Figures 3b and c) . Thus, the activity of the osteocalcin promoter transduced by the adenoviral vector was successfully enhanced by VD 3 in the osteocalcin-expressing cells with a sufficient AGTE, and interestingly, the activity levels were much lower in the osteosarcoma cell lines than the prostate cancer cell lines. More importantly and notably, the activity of the osteocalcin promoter in the most of these cells, including the VD 3 -enhanced activity in osteocalcin-expressing cells, was much lower than that of the RSV promoter.
Low E1BD55K expression levels after Surv.m-CRA-OCp infection Because the osteocalcin promoter had weak activity that was enhanced by VD 3 , the osteocalcin promoter is an ideal model to answer our question, that is, how much activity of the altered E1B promoter is necessary for exhibiting sufficient therapeutic effects. To this end, we generated Surv.m-CRA-CMVp and Surv.m-CRA-OCp, in which E1BD55K is regulated by the ubiquitously active CMV promoter and osteocalcin promoter, respectively, and E1A is regulated by the survivin promoter (Figure 4a) . We used the CMV promoter because we previously determined that the CMV promoter had stronger (almost 
10-fold) activity than the RSV promoter in most cell types.
15 E1BD55K protein expression was quantified by western blot analyses of cell extracts that were collected 3 days after the HOS-MNNG cells were infected with the noted adenoviruses in the presence or absence of VD 3 (Figure 4b ). Surv.m-CRA-CMVp infection resulted in high E1BD55K expression regardless of VD 3 stimulation, whereas uninfected cells and cells infected with the control E1-deleted adenovirus had no E1BD55K expression. Surv.m-CRA-OCp infection induced much lower E1BD55K expression than Surv.m-CRA-CMVp infection, even when E1BD55K expression was successfully enhanced by VD 3 . Thus, the weak activity of the osteocalcin promoter consistently resulted in low E1BD55K expression in osteocalcin-expressing cells that had been infected with Surv.m-CRA-OCp.
Weak E1BD55K expression levels are sufficient to induce significant m-CRA-associated cytotoxicity To examine whether the E1BD55K expression levels correlate with the efficiency of viral replication and the resulting anticancer effects of m-CRA, the viability of HOS-MNNG osteosarcoma and PC-3 prostate cancer cells were analyzed 7 days after they had been infected with Surv.m-CRA-OCp, and then cultured with or without VD 3 . Both Surv.m-CRA-CMVp and Surv.m-CRA-OCp demonstrated significant cytotoxic effects regardless of VD 3 compared to the control replicationdeficient adenovirus (Ad.dE1.3). Notably, culturing HOS-MNNG osteosarcoma cells with VD 3 , which clearly enhanced osteocalcin promoter activity and E1BD55K expression in Surv.m-CRA-OCp (Figures 3b and c and  4b) , did not increase the cytotoxic effects of Surv.m-CRAOCp (Figure 4c ). The same result was found with PC-3 prostate cancer cells. Thus, even drastic differences in the E1BD55K expression levels did not lead to significant differences in cytotoxicity, and it was particularly interesting that very weak E1BD55K expression was sufficient to achieve significant cytotoxic effects with m-CRAs. (Figure 4b ) started exhibiting cytopathic effects that were microscopically characteristic of oncolytic adenovirus, that is, cell swelling and detaching from the dish, and were similar to those observed in Surv.m-CRA-CMVp-infected cells (data not shown). On day 3, both groups showed a prominent and significant reduction in cell viability, as accurately determined by the WST-8 assay ( Figure 5 ). Although Surv.m-CRA-CMVp demonstrated slightly more efficient cytotoxic effects than Surv.m-CRA-OCp in HOS-MNNG cells on day 3, there was no difference between the two groups on day 5. On the other hand, the viability of PC-3 prostate cancer cells, which have stronger osteocalcin promoter activity than osteosarcoma cells, but weaker osteocalcin promoter activity than RSV promoter activity (Figure 3) , was not significantly different between Surv.m-CRA-CMVp and Surv.m-CRA-OCp on day 3 or 5 ( Figure 5) . Thus, Surv.m-CRA-OCp may generally confer sufficient anticancer effects to osteocalcin-expressing cancer cells, including not only prostate cancer cells, but also osteosarcoma cells in which the E1BD55K expression levels are very low in the absence of VD 3 .
On the other hand, our previous study demonstrated that low doses of Surv.m-CRA-CMVp, which may be one of the best CRAs both in terms of cancer specificity and anticancer efficiency, 7 did not induce significant cell death in normal cells. Nevertheless, there is a possibility that higher doses of any CRA may induce nonspecific cytotoxic effects in normal cells. To examine whether Surv.m-CRA-OCp increases the target specificity to 
NHOst osteoblasts when these cells were infected with Surv.m-CRAs at an MOI of 100 ( Figure 5 ). NHOst cells that were infected with any of the Surv.m-CRAs at an MOI of 10 did not undergo cell death after 3 or 5 days (data not shown). These in vitro data suggest that the regulation of E1BD55K expression by a cancer/tissue-specific promoter, regardless of its activity, results in more effective m-CRAs that efficiently kill the targeted cancer, but have significantly reduced nonspecific toxicity in normal cells.
Surv.m-CRA-OCp and Surv.m-CRA-CMVp exhibit the same anticancer effects in vivo Using an animal model of pre-established subcutaneous tumors, we examined whether Surv.m-CRA-OCp had the same in vivo therapeutic potential as Surv.m-CRA-CMVp in the absence of VD 3 . Two intratumoral injections of Surv.m-CRA-OCp (1 Â 10 8 PFU per time) on days 0 and 3 significantly inhibited tumor growth compared with the same dose of Ad.dE1.3. There were statistically significant differences in the tumor size between the Surv.m-CRAand Ad.dE1.3-treated mice, but there were no differences between Surv.m-CRA-OCp-and Surv.m-CRA-CMVptreated animals (Figures 6a and b) . It should be noted that the actual therapeutic effects of both Surv.m-CRAs were more significant based on microscopic analyses (Figure 6c) . The tumor nodules in Surv.m-CRA-treated mice contained large necrotic areas, but Ad.dE1.3-treated mice consisted primarily of viable tumor cells that histologically exhibited active malignant features. It should also be noted that the viral dose (1 Â 10 8 PFU per injection) in this study was much smaller than that used in many previous studies (approximately 1 Â 10 9 PFU), suggesting that more viral doses in future preclinical and clinical studies may result in enhanced efficacy. 26, 27 Thus, both the in vitro and in vivo therapeutic potential of Surv.m-CRA-OCp and Surv.m-CRA-CMVp for osteosarcoma in the absence of VD 3 was comparable, suggesting that low E1BD55K expression, that is, extremely weak activity of the altered E1B promoter, is sufficient to exert actual anticancer therapeutic effects.
Discussion
It has been uncertain whether replacing the E1B promoter with a cancer/tissue-specific promoter in addition to modified E1A regulation is more beneficial because previous studies did not examine the reduced anticancer effects. 9, 10 Furthermore, it is important to note that none of the previous studies examined the necessary activity of an altered E1B promoter to increase the cancer specificity without reducing the anticancer effects. In this regard, the following two points should be noted. First, the activities of cancer/tissue-specific promoters vary to a large degree, and many of them are typically lower than the characteristic constitutively and ubiquitously active promoters, including the RSV and CMV promoters. [13] [14] [15] Second, it is necessary to achieve optimal expression levels of certain genes and optimal activities of promoters driving certain genes to obtain correct and preferential functions. For instance, we previously revealed that an overly robust promoter clearly induced nonspecific cytotoxicity without increasing the anticancer effects and that a relatively weak promoter was suitable to drive a suicide gene from a clinical perspective. 15 Conversely, we also demonstrated that the activities of some tissue-specific promoters are too weak to directly visualize the reporter EGFP gene in target cells, and that it was necessary to enhance the activity of some tissue-specific promoters for this purpose.
14 These lessons illustrate the importance of determining the necessary expression levels of E1B/E1BD55K and the necessary activity of the cancer/tissue-specific promoter driving E1B/E1BD55K to E1B promoter activity for safer and potent m-CRAs Y Horikawa et al unexpected, but beneficial because these results indicate that most cancer/tissue-specific promoters can be used and illustrate that this principle may be, at least in part, generalized for the future development of this type of m-CRA (that is, two different promoters driving E1A and E1BD55K). On the other hand, previous studies showed that the E1A and E1B proteins must function in concert to activate effectively the transcription of other adenoviral genes, leading to efficient viral replication. 28 One widely accepted speculation on the role of E1B/ E1BD55K in adenoviral replication is that the antiapoptotic effects of E1BD55K prevent the early onset of cell death, providing extended periods for efficient viral replication in living cells. 29 A detailed examination of this molecular mechanism is beyond the scope of this study because part of the independent and diverse biological functions of the E1B protein may not simply reflect the overall virological functions of E1B in concert with other viral proteins. Nevertheless, these results further highlight the importance of the E1BD55K protein in adenoviral replication, particularly in the development of ideal m-CRAs.
This study also provides important information for future clinical trials that examine the efficacy of Surv.mCRAs to treat a variety of cancers, including the ability of Surv.m-CRA-OCp to treat osteosarcoma or prostate cancer. Clinical trials that have examined intratumoral injections of simple CRAs, in which E1A is regulated by a single cancer-specific promoter, demonstrated sufficient safety with no reports of lethal adverse effects. 30, 31 However, to date, there are no reports of clinical trials that have examined or sufficiently assessed the safety of systemic injections of simple CRAs, even though systemic injections may be more effective to treat disseminated cancer cell metastases, including metastatic osteosarcoma in lung, for which current therapies are ineffective. 1, 20, 32 The improved m-CRAs that were generated based on these results, including Surv.m-CRA-OCp, may facilitate clinical trials on systemic m-CRA therapy. However, careful and extensive preclinical studies should be performed.
In conclusion, replacing the E1B promoter with a different cancer/tissue-specific promoter, in addition to cancer-specific regulation of E1A, results in more effective m-CRAs that have high anticancer efficacy and increased safety. Surprisingly, but favorably, it is not essential for m-CRAs to use an altered E1B promoter with strong activity, indicating that the majority of cancer/tissue-specific promoters can be used to generate ideal m-CRAs. All of these results will greatly contribute to the development of highly effective m-CRA-based cancer therapy.
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